Media OutReach

NEW YORK, US – Media OutReach Newswire – 14 September 2025 – IVD Medical Holding Limited (01931.HK) officially announced its name change. Its English name was changed to “ETHK Labs Inc.”. This move marks a comprehensive strategic upgrade, shifting the company’s focus to core technology research and development and output for the digital industry and on-chain financial ecosystem. Through this name change, IVD Medical Holding Limited aims to more accurately reflect its new position as a key technology provider for the ” ETHK ” on-chain financial ecosystem and further enhance the group’s competitiveness and influence in the global digital asset ecosystem. Hashtag: #IVDMedical The issuer is solely responsible for the content of this announcement.

NEW YORK, US – Media OutReach Newswire – 14 September 2025 – IVD Medical Holding Limited (01931.HK) released an announcement stating its collaboration with ETHK Group, a global on-chain financial ecosystem investment holding group, to jointly establish two new companies, ETHK Inc and ETHK HOLDINGS LIMITED. ETHK Group focuses on building a global on-chain financial ecosystem, and its global perspective and ecosystem resources will provide critical support for the joint venture’s initial development. This collaboration is a strategic upgrade of IVD Medical Holding Limited’s “building RWA platform technology ecosystem” and “exploring on-chain finance” initiatives. It marks a leap from focusing on RWA trading technology to covering the entire on-chain financial ecosystem, including underlying technology, asset classes, and global compliance, with the potential to seize the global trend of digitalizing financial assets and open up a new growth curve. Hashtag: #IVDMedical The issuer is solely responsible for the content of this announcement.

HONG KONG SAR – Media OutReach Newswire – 13 September 2025 – The 10th Belt and Road Summit was successfully held at the Hong Kong Convention and Exhibition Centre from September 10 to 11, 2025. China Telecom Global Limited (hereinafter referred to as “China Telecom Global”) made a strong appearance under the theme “Empowering the New Silk Road via AI for Good.” The company spotlighted three key areas—its OneGrowth Global Partnership Program, AI global capabilities, and AI applications. Through flagship case studies, interactive showcases, and live demonstrations, China Telecom systematically presented its cloud-network-intelligence infrastructure and AI innovations along the Belt and Road. This highlighted its comprehensive strength and firm commitment to driving regional cooperation and development through digital technologies. On the opening day, Ms. Wu Ting, Director of AI Business at China Telecom Global, delivered a keynote speech titled “A Smarter Silk Road Future: China Telecom Global’s Global AI Capability Blueprint.” Her presentation provided an in-depth overview of China Telecom’s AI framework and capabilities, unveiling a series of innovative achievements and practical applications. These included cutting-edge solutions such as the OneTouch AI Training-Inference Integrated Machine, the AIGC Security Protection System, and the Xingchen Intelligent Agent Platform. Together, these offerings underscored the company’s leadership in AI research, development, and industrial applications. Drawing on multiple real-world cases, Ms. Wu also shared how China Telecom leverages its strengths in building international digital infrastructure and delivering intelligent solutions that empower enterprises to expand globally. At this year’s exhibition, China Telecom Global showcased multiple interactive highlights centered around its OneGrowth Global Partnership Program and AI global capabilities, offering a comprehensive presentation of its strengths in “AI+” technologies and ecosystem collaboration. AI Empowerment, Joint Innovation, Global Cooperation for a New Digital Ecosystem Within the OneGrowth Global Partnership Program segment, China Telecom Global highlighted the three major ecosystem directions introduced in June 2025 under the program. Guided by its four core principles—co-creation, co-sharing, co-governance, and win-win collaboration—the company outlined three focus areas: “AI + Digital Intelligence Enablement,” “AI + Ubiquitous Mobility,” and “AI + Innovative Services.” AI + Digital Intelligence Enablement: Establishing a global intelligent computing scheduling platform that integrates intelligent and general computing services, while jointly developing scenario-based digital intelligence enablement platforms with partners. AI + Ubiquitous Mobility: Leveraging its multidimensional communications network—spanning land, sea, air, and space—for ubiquitous connectivity, the company is working with global partners in key areas such as 5G, satellite communications, and the Internet of Vehicles. AI + Innovative Services: Showcasing ecosystem collaboration in visual networking through the Tianyi International Visual Networking Platform, a cross-border platform that integrates capabilities across AI algorithms, devices, cloud services, and applications. This provides customers with one-stop services tailored to diverse business needs. In the AI Global Capabilities segment, China Telecom Global not only showcased its global digital infrastructure—including a resource network of 53 submarine cables, 251 international points of presence, and 15 overseas intelligent computing centers—but also emphasized the capabilities of its two flagship computing hubs: the Tseung Kwan O Intelligent Computing Center in Hong Kong and the Jakarta Intelligent Computing Center in Indonesia. These highlighted the company’s core strengths in strengthening the foundation of the “Digital Silk Road” and enabling regional enterprise transformation. China Telecom Global also presented a portfolio of AI solutions and benchmark cases, such as 5GC scenario applications and low-altitude economy service systems. Real-world examples—including Chinese automotive manufacturers expanding into Europe and global operations by gaming companies—demonstrated the company’s tangible achievements along the Belt and Road, underscoring its leadership in driving industry digitalization and supporting enterprises in going global. Meanwhile, the AI interactive experience and showcase area attracted strong engagement, featuring projects such as AI-powered Opera Face-Changing, 5GC Robotic Dogs, and the Tianshu Drone. These interactive demonstrations vividly combined traditional culture with cutting-edge technologies, reflecting China Telecom Global’s innovative expertise across 5G, artificial intelligence, IoT, and the emerging low-altitude economy, while drawing enthusiastic participation from attendees. During the exhibition, China Telecom Global engaged in in-depth discussions with customers and partners from around the world to explore new opportunities for digital economy development under the Belt and Road Initiative. Looking ahead, the company will continue to leverage its advantages in cloud-network resources, AI technologies, and global service capabilities to deliver efficient and reliable digital solutions, advancing the construction of the Digital Silk Road to new heights. Through its participation in the summit, China Telecom Global demonstrated its strong capabilities in resource integration, technological innovation, and ecosystem collaboration as a world-class provider of digital intelligence services—reinforcing its unwavering commitment to empowering high-quality Belt and Road development through technological innovation and building a smarter future together. Hashtag: #ChinaTelecomGlobal The issuer is solely responsible for the content of this announcement.

LONG ISLAND, US – Media OutReach Newswire – 13 September 2025 – Garrett Taylor, CRPC®, Founder and Managing Partner of Coastline Wealth Management, has earned a place on Forbes’ 2025 Best-in-State Wealth Advisors list, ranking #40 in New York. He was named one of Long Island Business News’ Most Influential Long Islanders in Banking and Finance. These two recognitions reflect Garrett’s consistent track record of helping clients and advisors grow with purpose. The Long Island Business News feature, published on April 18, outlines Garrett’s leadership and the positive impact he’s had across the financial space. Garrett started Coastline Wealth Management in 2012. Since then, the firm has grown to manage over $4.2 billion in assets and now supports more than 7,000 client accounts. This growth has come from steady momentum and several business acquisitions. Today, Coastline works with advisors to help them shift their practices with care and confidence. Garrett has received several honors in the past, including recognition on Forbes’ Next-Gen Advisor lists and InvestmentNews’ 40 Under 40. He’s also been featured in earlier Long Island Business News awards for leadership. Beyond his work, he supports Make-A-Wish of Suffolk County and co-founded the Long Island chapter of the Entrepreneur Organization (EO). Hashtag: #CoastlineWealthManagement The issuer is solely responsible for the content of this announcement. Coastline Wealth Management Coastline Wealth Management, founded in 2012, is a Long Island, NY-based independent wealth management platform with over $4.2 billion of assets under management/advisement. Coastline services over 7,000 client accounts primarily across the East Coast of the United States. The Company, whose core focus is servicing its client base, has grown by a series of acquisitions as it continues to build its industry-leading, technology-enabled platform. Coastline continues to be a leading consolidator in the wealth management industry and is actively pursuing additional wealth advisor acquisitions (~$50MM to $500MM in assets) as part of its core growth story. By focusing on maximizing the value of advisory practices, Coastline empowers advisors to create sustainable, long-term strategies for transitioning their businesses, ensuring both financial stability and continuity for their clients. Its expertise in navigating the complexities of succession planning enables advisors to secure their legacy while optimizing growth potential, ultimately fostering a seamless transition that benefits all stakeholders involved.

MUNICH, GERMANY – Media OutReach Newswire – 13 September 2025 – COOFANDY, EKOUAER, and Zeagoo are excited to announce their participation in the 2025 Munich Oktoberfest, alongside a special offline pop-up event in partnership with Substanz Club, one of the city’s most iconic music bars. The event will take place from September 20 to 22 at Substanz Club, located just 700 meters from the main festival grounds. Centered around the theme “More Beer, More Bold, More You!”, the collaboration blends traditional festival spirit with modern fashion culture. This collaboration marks the brands’ first appearance at a globally renowned cultural event and underscores their collective focus on delivering immersive, high-impact experiences that connect fashion with local culture and community. By embedding their presence within a setting that blends tradition with global visibility, COOFANDY, EKOUAER, and Zeagoo seek to strengthen their footprint in the European market and explore new expressions of fashion within the context of cultural celebration. Three Brands, Three Immersive Zones Three distinct brand zones offer playful, hands-on experiences that bring each identity to life. COOFANDY: Guests take on a stylish spin on the Oktoberfest “Masskrug” lift, snap retro-inspired photos, and receive swag including 400 canvas bags, 1,200 intro cards, and 150 hats (50/day). EKOUAER: The “Blind Touch Challenge” highlights signature soft fabrics in a cozy, festive setting, with 400 bags, 1,200 cards, and 90 eye masks (30/day). Zeagoo: Visitors style a festival outfit in 30 seconds and pose in a selfie frame to win 400 bags, 1,200 cards, and 100 gift boxes (33/day). Over 3,600 branded gifts will be distributed during the three-day event—leaving guests with lasting, shareable impressions. From Street Style to Screen Share: A Connected Brand Experience Influencers will join the Substanz Club activation, sharing real-time content with hashtags like #BeerFashionClash, #Oktoberfit, and #MünchenStyle to drive engagement and visibility. From Sept 10 to Oct 10, COOFANDY, EKOUAER, and Zeagoo are offering 15–20% off select items on Amazon Germany and UK—bridging the in-person experience with online reach. Select hero products from each brand will be featured as part of the promotion, combining festive flair with comfort and style—perfect for Oktoberfest. From COOFANDY, the Men’s Stretch Slip-On Jeans offer all-day comfort with an elastic waistband and rugged design—ideal for festival fun and casual outings. The Knitted Short-Sleeve Turtleneck Shirt adds a modern edge to traditional looks, great for layering or standing out in the beer tent. EKOUAER brings cozy essentials like the Women’s Long-Sleeved Thermal Tops, perfect for layering during crisp Oktoberfest mornings. The V-Neck Button-Down Nightdress offers soft comfort and relaxed style, ideal for winding down after a full day of celebration. Zeagoo channels Bavarian charm with the Lace Dirndl Blouse with Half Sleeves, featuring floral lace and pearl buttons for a classic festival look. The Short-Sleeve V-Neck Dirndl Blouse combines vintage embroidery with a flattering fit—perfect for both Oktoberfest and everyday styling. Looking Ahead Through immersive, shareable moments, COOFANDY, EKOUAER, and Zeagoo brought their values to life in meaningful, memorable ways. Moving forward, they’ll continue investing in cross-cultural storytelling, experiential retail, and digitally connected campaigns that deepen engagement across borders and platforms. Hashtag: #COOFANDY The issuer is solely responsible for the content of this announcement.

Zhangqiu District, Jinan City, Shandong Province – September 2025 HONG KONG SAR – EQS Newswire – 12 September 2025 – Uni-Bio Science Group (“the Group”) is pleased to announce the signing of a strategic cooperation agreement with Kexing Biopharm (Stock Code: 688136.SH), a leading biopharmaceutical company with extensive expertise in global commercialization. Under this landmark agreement, Beijing Genetech Pharmaceutical Co., Ltd. (“Beijing Genetech”), a subsidiary of the Group, has granted Kexing Biopharm exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico (“Cooperation Regions”). Bogutai® is expected to complete registration and generate revenue in the Cooperation Regions as early as the end of 2026. The signing ceremony, held in Zhangqiu District, Jinan City, marks a pivotal step in the Group’s international expansion and its commitment to advancing osteoporosis care worldwide. Pioneering Osteoporosis Treatment with Proven Results Bogutai® is a recombinant human parathyroid hormone analog (PTH1–34), an anabolic treatment for osteoporosis that has been widely recognized for its efficacy and safety. Recommended by numerous domestic and international clinical guidelines, Teriparatide is particularly effective in improving bone microarchitecture and reducing fracture risk in postmenopausal women at high risk of fractures. Since its launch in China in March 2024, Bogutai® has demonstrated rapid market adoption, achieving a remarkable revenue growth of 248.9% year-on-year in the first half of 2025, reaching approximately HK$65.6 million. This impressive performance underscores the strong demand for innovative osteoporosis therapies and highlights the untapped potential of Bogutai® in global markets. Addressing the Global Osteoporosis Epidemic Osteoporosis, often referred to as a “silent killer,” affects over 200 million people globally, with the aging population exacerbating its prevalence. Early-stage osteoporosis is typically asymptomatic, leading to delayed diagnoses and severe complications such as fractures. In China, for example, only 6.5% of individuals receive osteoporosis treatment within six months of a fracture. Similarly, emerging markets across the Middle East and North Africa face low diagnosis and treatment rates despite growing awareness and significant patient populations. Injectable therapies like Teriparatide have been recommended by the Guidelines for Rational Drug Use of Osteoporosis in Primary Care (2021) for patients unable to tolerate oral medications, those with poor adherence, or individuals at high risk of fractures, including elderly patients with multiple vertebral or hip fractures. With its targeted mechanism of action as a bone-forming agent, Bogutai® is uniquely positioned to address this unmet medical need in both established and emerging markets. It is estimated that the osteoporosis market in the Cooperation Regions is nearly USD 1.5 billion, with a patient population exceeding 10 million. A Collaboration Built on Complementary Strengths Commenting on the partnership, Mr. Kingsley Leung, Chairman of Uni-Bio Science Group, said: “Teriparatide Injection is a transformative therapy with immense potential in overseas markets. By partnering with Kexing Biopharm, a company with a robust international commercialization network and proven operational expertise, we are confident in our ability to bring Bogutai® to patients in need across key regions. This collaboration represents a critical step in our mission to improve global bone health.” Mr. Zhao Yanqing, General Manager of Kexing Biopharm, added: “We are excited to join forces with Uni-Bio Science Group to unlock the regional potential of Bogutai®. With our established capabilities in regulatory approvals and market promotion, we aim to accelerate product registration and commercialization, ensuring that this innovative therapy reaches patients quickly and effectively.” Enhancing Global Competitiveness in Osteoporosis Care With over 20 years of international commercialization experience, Kexing Biopharm has built a strong marketing network spanning the European Union and emerging markets. The addition of Bogutai® to its portfolio complements its existing success with previously introduced denosumab injection, creating a comprehensive suite of osteoporosis treatments that combines “anti-resorptive” and “bone-forming” therapies. This synergy enhances the competitiveness of both companies in addressing the growing global demand for osteoporosis care. For Uni-Bio Science Group, this partnership is a key milestone in its internationalization strategy. Bogutai® is expected to generate revenue in the Cooperation Regions as early as the end of 2026, and with its competitive pricing, it may achieve higher profit margins. Beyond the collaboration with Kexing Biopharm, the Group is actively pursuing FDA approval for Bogutai® in the United States, having already received a waiver for in vivo bioequivalence studies. With this expedited regulatory pathway, FDA approval is anticipated in 2027, further solidifying the Group’s position as a leader in osteoporosis treatment. The Group is also advancing innovative pipeline products, including Uni-PTH (microneedle) for osteoporosis and UB107 (a Class III medical device) for bone repair, reinforcing its commitment to addressing unmet medical needs in bone metabolism and regenerative medicine. Shaping the Future of Osteoporosis Treatment Looking ahead, Uni-Bio Science Group remains dedicated to expanding its global footprint, deepening strategic partnerships, and accelerating the development of innovative therapies. By bringing Chinese innovation to the world, the Group aims to improve the lives of osteoporosis patients and set new standards in bone health and regenerative medicine. Hashtag: #UniBioScienceGroup The issuer is solely responsible for the content of this announcement. About Bogutai® (Teriparatide Injection) Bogutai® (Teriparatide Injection) is a biologically expressed recombinant human parathyroid hormone analog (PTH1–34), representing the active 34-amino-acid N-terminal region of the full 84-amino-acid human parathyroid hormone. This advanced therapeutic agent is specifically indicated for postmenopausal women with osteoporosis who are at high risk of fractures. Bogutai® exerts its effects by stimulating osteoblast activity, promoting new bone formation, and increasing bone mineral density (BMD). Unlike antiresorptive therapies that primarily inhibit bone resorption, Bogutai® actively enhances bone remodeling by increasing osteoblast-mediated bone deposition while indirectly regulating osteoclast activity to maintain a balanced bone turnover. This anabolic mechanism makes it a highly effective treatment option for reducing the risk of fractures and improving skeletal integrity in patients with severe osteoporosis. About Uni-Bio Science Group Uni-Bio Science Group Limited (Stock Code: HK 00690) is a biopharmaceutical company dedicated to utilizing new synthetic biology technology to develop next generation regenerative therapies in the orthopedics, ophthalmology, dermatology and medical aesthetics. The Group also has three GMP manufacturing bases